Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
EMBO Rep ; 23(8): e54483, 2022 08 03.
Artículo en Inglés | MEDLINE | ID: mdl-35758159

RESUMEN

DNA lesions occur across the genome and constitute a threat to cell viability; however, damage at specific genomic loci has a relatively greater impact on overall genome stability. The ribosomal RNA gene repeats (rDNA) are emerging fragile sites. Recent progress in understanding how the rDNA damage response is organized has highlighted a key role of adaptor proteins. Here, we show that the scaffold tumor suppressor RASSF1A is recruited to rDNA breaks. RASSF1A recruitment to double-strand breaks is mediated by 53BP1 and depends on RASSF1A phosphorylation at Serine 131 by ATM kinase. Employing targeted rDNA damage, we uncover that RASSF1A recruitment promotes local ATM signaling. RASSF1A silencing, a common epigenetic event during malignant transformation, results in persistent breaks, rDNA copy number alterations and decreased cell viability. Overall, we identify a novel role for RASSF1A at rDNA break sites, provide mechanistic insight into how the DNA damage response is organized in a chromatin context, and provide further evidence for how silencing of the RASSF1A tumor suppressor contributes to genome instability.


Asunto(s)
Roturas del ADN de Doble Cadena , Proteínas de Unión al ADN , Proteínas Supresoras de Tumor/metabolismo , Proteínas de la Ataxia Telangiectasia Mutada/genética , Proteínas de la Ataxia Telangiectasia Mutada/metabolismo , Daño del ADN , Reparación del ADN , ADN Ribosómico/genética , Proteínas de Unión al ADN/genética , Proteínas de Unión al ADN/metabolismo , Inestabilidad Genómica , Humanos , Fosforilación , Transducción de Señal/genética , Proteína 1 de Unión al Supresor Tumoral P53/genética , Proteína 1 de Unión al Supresor Tumoral P53/metabolismo
2.
Nat Commun ; 9(1): 2280, 2018 06 11.
Artículo en Inglés | MEDLINE | ID: mdl-29891926

RESUMEN

Defects in DNA repair can cause various genetic diseases with severe pathological phenotypes. Fanconi anemia (FA) is a rare disease characterized by bone marrow failure, developmental abnormalities, and increased cancer risk that is caused by defective repair of DNA interstrand crosslinks (ICLs). Here, we identify the deubiquitylating enzyme USP48 as synthetic viable for FA-gene deficiencies by performing genome-wide loss-of-function screens across a panel of human haploid isogenic FA-defective cells (FANCA, FANCC, FANCG, FANCI, FANCD2). Thus, as compared to FA-defective cells alone, FA-deficient cells additionally lacking USP48 are less sensitive to genotoxic stress induced by ICL agents and display enhanced, BRCA1-dependent, clearance of DNA damage. Consequently, USP48 inactivation reduces chromosomal instability of FA-defective cells. Our results highlight a role for USP48 in controlling DNA repair and suggest it as a potential target that could be therapeutically exploited for FA.


Asunto(s)
Reparación del ADN/genética , Reparación del ADN/fisiología , Anemia de Fanconi/genética , Anemia de Fanconi/metabolismo , Proteasas Ubiquitina-Específicas/genética , Proteasas Ubiquitina-Específicas/metabolismo , Proteína BRCA1/metabolismo , Sistemas CRISPR-Cas , Línea Celular , Inestabilidad Cromosómica , Daño del ADN , Anemia de Fanconi/terapia , Proteína del Grupo de Complementación A de la Anemia de Fanconi/deficiencia , Proteína del Grupo de Complementación A de la Anemia de Fanconi/genética , Proteína del Grupo de Complementación A de la Anemia de Fanconi/metabolismo , Proteína del Grupo de Complementación C de la Anemia de Fanconi/deficiencia , Proteína del Grupo de Complementación C de la Anemia de Fanconi/genética , Proteína del Grupo de Complementación C de la Anemia de Fanconi/metabolismo , Proteína del Grupo de Complementación D2 de la Anemia de Fanconi/deficiencia , Proteína del Grupo de Complementación D2 de la Anemia de Fanconi/genética , Proteína del Grupo de Complementación D2 de la Anemia de Fanconi/metabolismo , Proteína del Grupo de Complementación G de la Anemia de Fanconi/deficiencia , Proteína del Grupo de Complementación G de la Anemia de Fanconi/genética , Proteína del Grupo de Complementación G de la Anemia de Fanconi/metabolismo , Proteínas del Grupo de Complementación de la Anemia de Fanconi/deficiencia , Proteínas del Grupo de Complementación de la Anemia de Fanconi/genética , Proteínas del Grupo de Complementación de la Anemia de Fanconi/metabolismo , Técnicas de Inactivación de Genes , Terapia Genética , Histonas/metabolismo , Humanos , Mutación , Recombinasa Rad51/metabolismo , Proteasas Ubiquitina-Específicas/deficiencia , Ubiquitinación
3.
Nat Commun ; 8(1): 1238, 2017 11 01.
Artículo en Inglés | MEDLINE | ID: mdl-29089570

RESUMEN

Maintenance of genome integrity via repair of DNA damage is a key biological process required to suppress diseases, including Fanconi anemia (FA). We generated loss-of-function human haploid cells for FA complementation group C (FANCC), a gene encoding a component of the FA core complex, and used genome-wide CRISPR libraries as well as insertional mutagenesis to identify synthetic viable (genetic suppressor) interactions for FA. Here we show that loss of the BLM helicase complex suppresses FANCC phenotypes and we confirm this interaction in cells deficient for FA complementation group I and D2 (FANCI and FANCD2) that function as part of the FA I-D2 complex, indicating that this interaction is not limited to the FA core complex, hence demonstrating that systematic genome-wide screening approaches can be used to reveal genetic viable interactions for DNA repair defects.


Asunto(s)
Reparación del ADN/genética , Proteína del Grupo de Complementación C de la Anemia de Fanconi/genética , Anemia de Fanconi/genética , RecQ Helicasas/genética , Sistemas CRISPR-Cas , Línea Celular , Daño del ADN , ADN Helicasas/genética , Proteína del Grupo de Complementación D2 de la Anemia de Fanconi/genética , Proteínas del Grupo de Complementación de la Anemia de Fanconi/genética , Células HEK293 , Haploidia , Humanos , Mutagénesis Insercional , NAD(P)H Deshidrogenasa (Quinona)/genética
4.
PLoS Genet ; 11(11): e1005645, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26544571

RESUMEN

Proper development of the immune system is an intricate process dependent on many factors, including an intact DNA damage response. The DNA double-strand break signaling kinase ATM and its cofactor NBS1 are required during T cell development and for the maintenance of genomic stability. The role of a second ATM cofactor, ATMIN (also known as ASCIZ) in T cells is much less clear, and whether ATMIN and NBS1 function in synergy in T cells is unknown. Here, we investigate the roles of ATMIN and NBS1, either alone or in combination, using murine models. We show loss of NBS1 led to a developmental block at the double-positive stage of T cell development, as well as reduced TCRα recombination, that was unexpectedly neither exacerbated nor alleviated by concomitant loss of ATMIN. In contrast, loss of both ATMIN and NBS1 enhanced DNA damage that drove spontaneous peripheral T cell hyperactivation, proliferation as well as excessive production of proinflammatory cytokines and chemokines, leading to a highly inflammatory environment. Intriguingly, the disease causing T cells were largely proficient for both ATMIN and NBS1. In vivo this resulted in severe intestinal inflammation, colitis and premature death. Our findings reveal a novel model for an intestinal bowel disease phenotype that occurs upon combined loss of the DNA repair cofactors ATMIN and NBS1.


Asunto(s)
Proteínas de Ciclo Celular/fisiología , Reparación del ADN , Activación de Linfocitos/fisiología , Proteínas Nucleares/fisiología , Linfocitos T/inmunología , Factores de Transcripción/fisiología , Animales , Colitis/inmunología , Daño del ADN , Proteínas de Unión al ADN , Inmunofenotipificación , Ratones , Especies Reactivas de Oxígeno/metabolismo , Receptores de Antígenos de Linfocitos T alfa-beta/genética , Recombinación Genética , Bazo/citología , Bazo/metabolismo
5.
Exp Cell Res ; 329(1): 85-93, 2014 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-25281304

RESUMEN

DNA replication is a fundamental process of the cell that ensures accurate duplication of the genetic information and subsequent transfer to daughter cells. Various pertubations, originating from endogenous or exogenous sources, can interfere with proper progression and completion of the replication process, thus threatening genome integrity. Coordinated regulation of replication and the DNA damage response is therefore fundamental to counteract these challenges and ensure accurate synthesis of the genetic material under conditions of replication stress. In this review, we summarize the main sources of replication stress and the DNA damage signaling pathways that are activated in order to preserve genome integrity during DNA replication. We also discuss the association of replication stress and DNA damage in human disease and future perspectives in the field.


Asunto(s)
Daño del ADN/genética , Replicación del ADN , Enfermedad/genética , Inestabilidad Genómica , Animales , Humanos
6.
DNA Repair (Amst) ; 24: 122-130, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25262557

RESUMEN

Unresolved replication intermediates can block the progression of replication forks and become converted into DNA lesions, hence exacerbating genomic instability. The p53-binding protein 1 (53BP1) forms nuclear bodies at sites of unrepaired DNA lesions to shield these regions against erosion, in a manner dependent on the DNA damage kinase ATM. The molecular mechanism by which ATM is activated upon replicative stress to localize the 53BP1 protection complex is unknown. Here we show that the ATM-INteracting protein ATMIN (also known as ASCIZ) is partially required for 53BP1 localization upon replicative stress. Additionally, we demonstrate that ATM activation is impaired in cells lacking ATMIN and we define that ATMIN is required for initiating ATM signaling following replicative stress. Furthermore, loss of ATMIN leads to chromosomal segregation defects. Together these data reveal that chromatin integrity depends on ATMIN upon exposure to replication-induced stress.


Asunto(s)
Proteínas de la Ataxia Telangiectasia Mutada/metabolismo , Replicación del ADN , Péptidos y Proteínas de Señalización Intracelular/metabolismo , Factores de Transcripción/metabolismo , Afidicolina/farmacología , Proteínas de la Ataxia Telangiectasia Mutada/genética , Ciclo Celular/fisiología , Segregación Cromosómica , Daño del ADN/efectos de los fármacos , Células HeLa/efectos de los fármacos , Humanos , Péptidos y Proteínas de Señalización Intracelular/genética , Transducción de Señal/genética , Factores de Transcripción/genética , Proteína 1 de Unión al Supresor Tumoral P53
7.
Nat Cell Biol ; 15(8): 967-77, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23851489

RESUMEN

The DNA damage response (DDR) pathway and ARF function as barriers to cancer development. Although commonly regarded as operating independently of each other, some studies proposed that ARF is positively regulated by the DDR. Contrary to either scenario, we found that in human oncogene-transformed and cancer cells, ATM suppressed ARF protein levels and activity in a transcription-independent manner. Mechanistically, ATM activated protein phosphatase 1, which antagonized Nek2-dependent phosphorylation of nucleophosmin (NPM), thereby liberating ARF from NPM and rendering it susceptible to degradation by the ULF E3-ubiquitin ligase. In human clinical samples, loss of ATM expression correlated with increased ARF levels and in xenograft and tissue culture models, inhibition of ATM stimulated the tumour-suppressive effects of ARF. These results provide insights into the functional interplay between the DDR and ARF anti-cancer barriers, with implications for tumorigenesis and treatment of advanced tumours.


Asunto(s)
Factor 1 de Ribosilacion-ADP/metabolismo , Proteínas de Ciclo Celular/metabolismo , Proteínas de Unión al ADN/metabolismo , Neoplasias/fisiopatología , Proteínas Serina-Treonina Quinasas/metabolismo , Proteína p14ARF Supresora de Tumor/metabolismo , Factor 1 de Ribosilacion-ADP/genética , Animales , Proteínas de la Ataxia Telangiectasia Mutada , Proteínas Portadoras/metabolismo , Ciclo Celular/fisiología , Proteínas de Ciclo Celular/genética , Línea Celular , Línea Celular Tumoral , Proteínas de Unión al ADN/genética , Regulación Neoplásica de la Expresión Génica , Células HeLa , Humanos , Masculino , Ratones , Quinasas Relacionadas con NIMA , Neoplasias/enzimología , Neoplasias/patología , Fosforilación , Proteínas Serina-Treonina Quinasas/genética , Estabilidad Proteica , Ribosomas/metabolismo , Transducción de Señal , Trasplante Heterólogo , Proteína p14ARF Supresora de Tumor/genética , Ubiquitina-Proteína Ligasas/metabolismo
8.
Int J Cancer ; 128(8): 1989-95, 2011 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-20549705

RESUMEN

The p14(ARF) is a key tumor suppressor induced mainly by oncogenic stimuli. Although p14(ARF) does not seem to respond to DNA damage, there are very few data regarding its role in other forms of stress, such as heat shock (HS) and oxidative stress (OS). Here, we report that suppression of p14(ARF) increased resistance to cell death when cells were treated with H(2) O(2) or subjected to HS. In this setting, protection from cell death was mediated by elevated levels and activity of ß-catenin, as downregulation of ß-catenin alleviated the protective role of p14(ARF) silencing. Moreover, Hsp70 was shown to regulate ß-catenin protein levels by interacting with p14(ARF) , suggesting that Hsp70, p14(ARF) and ß-catenin form a regulatory network. This novel pathway triggers cell death signals when cells are exposed to HS and OS.


Asunto(s)
Apoptosis , Proteínas del Choque Térmico HSP72/metabolismo , Respuesta al Choque Térmico , Estrés Oxidativo , Proteína p14ARF Supresora de Tumor/metabolismo , beta Catenina/metabolismo , Western Blotting , Proliferación Celular , Citometría de Flujo , Regulación Neoplásica de la Expresión Génica , Proteínas del Choque Térmico HSP72/genética , Humanos , Inmunoprecipitación , Luciferasas/metabolismo , Neoplasias/genética , Neoplasias/metabolismo , Neoplasias/patología , ARN Mensajero/genética , ARN Interferente Pequeño/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Células Tumorales Cultivadas , Proteína p14ARF Supresora de Tumor/antagonistas & inhibidores , Proteína p14ARF Supresora de Tumor/genética , Regulación hacia Arriba , beta Catenina/genética
9.
J Cell Mol Med ; 14(9): 2264-7, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20716117

RESUMEN

DNA lesions trigger the DNA damage response (DDR) machinery, which protects genomic integrity and sustains cellular survival. Increasing data underline the significance of the integrity of the DDR pathway in chemotherapy response. According to a recent work, persistent exposure of A549 lung carcinoma cells to doxorubicin induces an initial DDR-dependent checkpoint response, followed by a later DDR-independent, but p27(Kip1)-dependent one. Prompted by the above report and to better understand the involvement of the DDR signaling after chemotherapeutic stress, we examined the potential role of the canonical DDR pathway in A549 cells treated with doxorubicin. Exposure of A549 cells, prior to doxorubicin treatment, to ATM, ATR and DNA-PKcs inhibitors either alone or in various combinations, revealed that the earlier documented two-step response was DDR-dependent in both steps. Notably, inhibition of both ATM and ATR or selective inhibition of ATM or DNA-PKcs resulted in cell-cycle re-entry despite the increased levels of p27(Kip1) at all time points analyzed. We further investigated the regulation of p27(Kip1) protein levels in the particular setting. Our results showed that the protein status of p27(Kip1) is mainly determined by p38-MAPK, whereas the role of SKP2 is less significant in the doxoroubicin-treated A549 cells. Cumulatively, we provide evidence that the DNA damage signaling is responsible for the prolonged cell cycle arrest observed after persistent chemotherapy-induced genotoxic stress. In conclusion, precise identification of the molecular mechanisms that are activated during the chemotherapeutic cycles could potentially increase the sensitization to the therapy applied.


Asunto(s)
Antineoplásicos/farmacología , Inhibidor p27 de las Quinasas Dependientes de la Ciclina/fisiología , Doxorrubicina/farmacología , Puntos de Control de la Fase G2 del Ciclo Celular/efectos de los fármacos , Células A549 , Proteínas de la Ataxia Telangiectasia Mutada/antagonistas & inhibidores , Cafeína/farmacología , Cromonas/farmacología , Daño del ADN , Proteína Quinasa Activada por ADN/antagonistas & inhibidores , Humanos , Morfolinas/farmacología , Pironas/farmacología , Proteínas Quinasas Asociadas a Fase-S/metabolismo , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
10.
Am J Pathol ; 175(1): 376-91, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19541929

RESUMEN

Osteosarcoma is the most common primary bone cancer. Mutations of the RB gene represent the most frequent molecular defect in this malignancy. A major consequence of this alteration is that the activity of the key cell cycle regulator E2F1 is unleashed from the inhibitory effects of pRb. Studies in animal models and in human cancers have shown that deregulated E2F1 overexpression possesses either "oncogenic" or "oncosuppressor" properties, depending on the cellular context. To address this issue in osteosarcomas, we examined the status of E2F1 relative to cell proliferation and apoptosis in a clinical setting of human primary osteosarcomas and in E2F1-inducible osteosarcoma cell line models that are wild-type and deficient for p53. Collectively, our data demonstrated that high E2F1 levels exerted a growth-suppressing effect that relied on the integrity of the DNA damage response network. Surprisingly, induction of p73, an established E2F1 target, was also DNA damage response-dependent. Furthermore, a global proteome analysis associated with bioinformatics revealed novel E2F1-regulated genes and potential E2F1-driven signaling networks that could provide useful targets in challenging this aggressive neoplasm by innovative therapies.


Asunto(s)
Neoplasias Óseas/metabolismo , Factor de Transcripción E2F1/metabolismo , Regulación Neoplásica de la Expresión Génica , Osteosarcoma/metabolismo , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Apoptosis/fisiología , Western Blotting , Neoplasias Óseas/genética , Línea Celular Tumoral , Proliferación Celular , Niño , Daño del ADN , Reparación del ADN , Proteínas de Unión al ADN/metabolismo , Factor de Transcripción E2F1/genética , Electroforesis en Gel Bidimensional , Femenino , Citometría de Flujo , Técnica del Anticuerpo Fluorescente , Humanos , Inmunohistoquímica , Etiquetado Corte-Fin in Situ , Masculino , Persona de Mediana Edad , Proteínas Nucleares/metabolismo , Osteosarcoma/genética , Proteína Tumoral p73 , Proteína p53 Supresora de Tumor/deficiencia , Proteínas Supresoras de Tumor/metabolismo , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...